About deCODE genetics

Headquartered in Reykjavik, Iceland, deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of drugs and diagnostics for common diseases. deCODE is a global leader in gene discovery - our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. The company currently has seven lead programs in drug discovery and development, including three in clinical development, and is broadening its pipeline through gene and target discovery work in 50 of the most common diseases.

deCODE is also leveraging its expertise in human genetics and integrated drug discovery and development capabilities to offer innovative products and services in DNA-based diagnostics, bioinformatics, genotyping, structural biology, drug discovery and clinical development.

From genes to diagnostics

From target discovery through product development, deCODE's work is powered by our population approach to human genetics. deCODE is the world leader in gene discovery in common diseases, and has isolated major genetic factors involved in public health challenges ranging from cardiovascular disease to cancer.

Because our gene discovery work underpins both diagnostic and drug discovery, we believe that our DNA-based diagnostic tests may also enable doctors to identify individuals likely to derive particular benefit from deCODE's developmental compounds or from existing medications.

To learn more about deCODE genetics, please visit: www.decode.com